Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03826433 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v11
  2. Primary completion date: Jun 30, 2025 to Dec 31, 2025
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v10
  3. Primary completion date: Jun 30, 2024 to Jun 30, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    v9
  4. Primary completion date: Dec 2023 to Jun 30, 2024
    • Study completion date: Jun 2024 to Dec 31, 2024
    v8
  5. Primary completion date: Dec 2022 to Dec 2023
    • Study completion date: Jun 2023 to Jun 2024
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jun 2022 to Dec 2022
    • Study completion date: Dec 2022 to Jun 2023
    v6
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: Jun 2021 to Jun 2022
    • Study completion date: Dec 2021 to Dec 2022
    v4
  4. Primary completion date: Jun 2020 to Jun 2021
    • Study completion date: Jun 2020 to Dec 2021
    • Study title shortened, about 2 words
    v3
  5. Study title revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat. 3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.
Trial Details
NCT Number NCT03826433
Lead Sponsor Sclnow Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Hepatitis B
Related terms Hepatitis B
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov